Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The closing price of Wave Life Sciences Ltd (NASDAQ: WVE) was $11.03 for the day, up 2.04% from the previous closing price of $10.81. In other words, the price has increased by $2.04 from its previous closing price. On the day, 0.64 million shares were traded.
Ratios:
Our analysis of WVE’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.90 and its Current Ratio is at 1.90. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.13.
On September 19, 2024, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $11.B. Riley Securities initiated its Buy rating on September 19, 2024, with a $11 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 25 ’24 when BOLNO PAUL sold 50,000 shares for $15.00 per share. The transaction valued at 750,000 led to the insider holds 217,351 shares of the business.
PAUL BOLNO bought 50,000 shares of WVE for $750,000 on Nov 25 ’24. On Nov 15 ’24, another insider, BOLNO PAUL, who serves as the President and CEO of the company, sold 51,234 shares for $14.32 each. As a result, the insider received 733,671 and left with 217,351 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 31.38 while its Price-to-Book (P/B) ratio in mrq is 11.56.
Stock Price History:
Over the past 52 weeks, WVE has reached a high of $16.74, while it has fallen to a 52-week low of $3.63. The 50-Day Moving Average of the stock is -11.83%, while the 200-Day Moving Average is calculated to be 19.89%.
Shares Statistics:
A total of 148.39M shares are outstanding, with a floating share count of 122.12M. Insiders hold about 19.93% of the company’s shares, while institutions hold 79.62% stake in the company.
Earnings Estimates
The company has 7.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.27, with high estimates of -$0.24 and low estimates of -$0.32.
Analysts are recommending an EPS of between -$1.02 and -$1.27 for the fiscal current year, implying an average EPS of -$1.19. EPS for the following year is -$0.97, with 8.0 analysts recommending between -$0.67 and -$1.15.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 9 analysts. It ranges from a high estimate of $70.2M to a low estimate of $1.76M. As of the current estimate, Wave Life Sciences Ltd’s year-ago sales were $29.06M
A total of 9 analysts have provided revenue estimates for WVE’s current fiscal year. The highest revenue estimate was $94.8M, while the lowest revenue estimate was $33.9M, resulting in an average revenue estimate of $52.13M. In the same quarter a year ago, actual revenue was $113.31MBased on 10 analysts’ estimates, the company’s revenue will be $69.54M in the next fiscal year. The high estimate is $107.33M and the low estimate is $6M.
